Rakuten Aspyrian Closes $284 Million Series C Financing for La...
SAN FRANCISCO, Dec. 21, 2018 /PRNewswire-AsiaNet/ -- Rakuten Aspyrian, a biotechnology company developing precision-targeted cancer therapies based on its proprietary Photoimmunotherapy platform, today announced that it has raised an additional $134 million in a second tranche of its Series C financ...
Read more https://view-release/?pr-id=76871